Ticagrelor: The First Reversibly Binding Oral P2Y 12 Receptor Antagonist

Abstract

Ticagrelor (AZD6140) is the first reversibly binding oral P2Y 12 receptor antagonist that blocks ADP‐induced platelet aggregation. Unlike thienopyridines, which irreversibly bind to the P2Y 12 receptor for the lifetime of the platelet, ticagrelor binds reversibly to the receptor and exhibits rapid onset and offset of effect, which closely follow drug exposure levels. Animal models indicate greater separation between antithrombotic effects and bleeding effects with ticagrelor than with thienopyridines. Unlike the thienopyridines, ticagrelor does not require metabolic activation. It is quickly absorbed and exhibits a rapid antiplatelet effect, with higher and more consistent levels of inhibition of platelet aggregation (IPA) being maintained across the dosing interval than with clopidogrel. IPA levels decline with plasma drug levels after discontinuation of dosing. In the phase II DISPERSE‐2 trial of 990 patients with non‐ST‐elevation acute coronary syndromes (ACS), ticagrelor treatment with 90 mg and 180 mg twice daily showed comparable rates of major and minor bleeding compared with clopidogrel 75 mg while there were numerically fewer myocardial infarctions. Ticagrelor resulted in greater IPA in clopidogrel‐naïve patients and produced substantial additional reductions in platelet aggregation activity in patients pretreated with clopidogrel. Ticagrelor treatment was well tolerated in DISPERSE‐2, and discontinuation rates were comparable to those observed for clopidogrel. An increased risk of mild to moderate dyspnea and mostly asymptomatic ventricular pauses were observed in phase II studies. The mechanisms for these effects are currently being investigated. The efficacy and safety of ticagrelor are being further evaluated in the phase III PLATO trial, involving approximately 18,000 patients with ACS, including both ST‐elevation and non‐ST‐elevation ACS.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 53

1. 1.

   Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.

   Not in our library10.1056/nejmoa050522

2. 2.

   Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.

   Not in our library10.1056/nejmoa010746

3. 3.

   Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. Circulation. 2007;116:803-877.

   Not in our library

4. 4.

   Bassand JP, Hamm CW, Ardissino D, for the Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-1660.

   Not in our library10.1093/eurheartj/ehm161

5. 5.

   Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, Herbert JM. The antiaggregation activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994;72:313-317.

   Not in our library

6. 6.

   Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166-171.

   Not in our library10.1161/01.cir.0000112378.09325.f9

7. 7.

   Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol. 2006;26:1895-1900.

   Not in our library10.1161/01.atv.0000223867.25324.1a

8. 8.

   Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81:735-741.

   Not in our library10.1038/sj.clpt.6100139

9. 9.

   Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003;91:1123-1125.

   Not in our library10.1016/s0002-9149(03)00163-2

10. 10.

    Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89:783-787.

    Not in our library

11. 11.

    Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246-251.

    Not in our library10.1016/j.jacc.2004.09.067

12. 12.

    Heptinstall S. Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes. J Thromb Haemost. 2006;4:539-541.

    Not in our library10.1111/j.1538-7836.2005.01777.x

13. 13.

    Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27:2420-2425.

    Not in our library10.1093/eurheartj/ehl275

14. 14.

    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-1516.

    Not in our library10.1016/j.jacc.2006.11.044

15. 15.

    Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Cathet Cardiovasc Intervent. 2003;59:295-302.

    Not in our library10.1002/ccd.10497

16. 16.

    Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.

    Not in our library10.1161/01.cir.0000072771.11429.83

17. 17.

    Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171-3175.

    Not in our library10.1161/01.cir.0000130846.46168.03

18. 18.

    Ajzenberg N, Aubry P, Huisse MG, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis. A case-control study. J Am Coll Cardiol. 2005;45:1753-1756.

    Not in our library10.1016/j.jacc.2004.10.079

19. 19.

    Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005;45:1392-1396.

    Not in our library10.1016/j.jacc.2005.01.030

20. 20.

    Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol. 2006;48:1339-1345.

    Not in our library10.1016/j.jacc.2006.06.049

21. 21.

    Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006;4:542-549.

    Not in our library10.1111/j.1538-7836.2005.01751.x

22. 22.

    Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48:1742-1750.

    Not in our library10.1016/j.jacc.2006.06.065

23. 23.

    Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. The role of dual drug resistance. J Am Coll Cardiol. 2006;47:27-33.

    Not in our library10.1016/j.jacc.2005.08.058

24. 24.

    Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention. Is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49:657-666.

    Not in our library10.1016/j.jacc.2006.10.050

25. 25.

    Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49:2312-2317.

    Not in our library10.1016/j.jacc.2007.01.094

26. 26.

    Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129:1439-1446.

    Not in our library10.1038/sj.bjp.0703237

27. 27.

    Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol. 2006;63:421-430.

    Not in our library10.1111/j.1365-2125.2006.02792.x

28. 28.

    Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166-1173.

    Not in our library10.1093/eurheartj/ehi877

29. 29.

    Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.

    Not in our library10.1056/nejmoa0706482

30. 30.

    van Giezen JJJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005;31:195-204.

    Not in our library10.1055/s-2005-869525

31. 31.

    Springthorpe B, Bailey A, Barton P, et al. From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett. 2007;17:6013-6018.

    Not in our library10.1016/j.bmcl.2007.07.057

32. 32.

    van Giezen JJJ, Berntsson P, Wissing B-M. Direct oral P2Y12 receptor antagonist AZD6140 potently and reversibly binds to the rh-P2Y12 receptor expressed on CHO-K1 cells. Arterioscler Thromb Vasc Biol. 2008;28:e-72.

    Not in our library

33. 33.

    Patil SBG, Norman KE, Robins SJ, Crosdale DJ, Nylander S, Francis SE, Storey RF. Inhibition of thrombosis by AZD6140 via selective blockade of the P2Y12 receptor in a murine laser-injury model. J Thromb Haemost. 2007;5.

    Not in our library

34. 34.

    Nilsson L, van Giezen JJJ, Greasley PJ. Evidence for distinct ligand binding sites on recombinant P2Y12 receptors. Circulation. 2006;114(Suppl II):II-248.

    Not in our library

35. 35.

    van Giezen JJJ, Nilsson L. AZD6140 binds to the rh-P2Y12 receptor expressed on CHO-K1 cells at a site distinct from the ADP binding site but antagonizes ADP-induced signaling. Arterioscler Thromb Vasc Biol. 2008;28:e-104.

    Not in our library

36. 36.

    van Giezen JJJ. Optimizing platelet inhibition. Eur Heart J Suppl. 2008;10(Suppl D):D23-D29.

    Not in our library

37. 37.

    van Giezen JJJ, Berntsson P. AZD6140 displays over 100-fold higher affinity for the P2Y12 receptor vs AZ11702105, a compound indistinguishable from the active metabolite of prasugrel, and is a more potent inhibitor of ADP-induced platelet aggregation. Arterioscler Thromb Vasc Biol. 2008;28:e-139-e-140.

    Not in our library

38. 38.

    van Giezen JJJ, Zachrisson H, Björkman JA. Reduced bleeding time prolongation for the reversible P2Y12 antagonist AZD6140 compared with clopidogrel and AZ11703072, a chemical compound indistinguishable from prasugrel, in both a rat and a dog model of combined thrombosis and hemostasis. Arterioscler Thromb Vasc Biol. 2008;28:e-140.

    Not in our library

39. 39.

    Wihlborg A-K, Wang L, Braun OÖ, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:1810-1815.

    Not in our library10.1161/01.atv.0000142376.30582.ed

40. 40.

    Svensson H, Erlinge D. The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in mouse aorta, in addition to established inhibitory effects on platelet aggregation. Arterioscler Thromb Vasc Biol. 2007;27:e-136.

    Not in our library

41. 41.

    Wang K, Zhou X, Zhou Z, et al. Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol. 2003;23:357-362.

    Not in our library10.1161/01.atv.0000052669.50791.0b

42. 42.

    Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, Peng Y, Penn MS. Adjunctive infusion of AZD6140, but not clopidogrel, with t-PA enables sustained coronary artery recanalization with recovery of myocardium perfusion in a canine model of myocardial infarction. J Am Coll Cardiol. 2009;53(Suppl A):A306-A307.

    Not in our library

43. 43.

    Björkman JA, Kirk I, van Giezen JJJ. AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion. Circulation. 2007;116(Suppl):II-28.

    Not in our library

44. 44.

    Butler K, Teng R. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, exhibits linear pharmacokinetics following multiple doses in healthy subjects, with greater and less variable inhibition of platelet aggregation compared with clopidogrel. Can J Clin Pharmacol. 2008;15:e684-e685.

    Not in our library

45. 45.

    Butler K, Oliver S, Teng R. A mass balance study of major excretory routes and metabolic profile following an oral [14C] dose of AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, in healthy male subjects. 2008.

    Not in our library

46. 46.

    Peters G, Robbie G. Single dose pharmacokinetics and pharmacodynamics of AZD6140. Haematologica. 2004;89(Suppl 7):14-15.

    Not in our library

47. 47.

    Teng R, Butler K. AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect, in healthy subjects. Can J Clin Pharmacol. 2008;15:e426.

    Not in our library

48. 48.

    Peters GR, Butler KA, Winter HR. Multiple-dose pharmacokinetics (PK) and pharmacodynamics (PD) of the oral reversible, orally active ADP receptor antagonist AZD6140. Eur Heart J. 2006;27(Suppl 1):P4556.

    Not in our library

49. 49.

    Butler K, Winter H, Mitchell P, Fox JC. Pharmacokinetics and pharmacodynamics of AZD6140, the first reversible oral P2Y12 receptor antagonist, administered with aspirin. J Clin Pharmacol. 2007;47.

    Not in our library

50. 50.

    Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038-1047.

    Not in our library10.1093/eurheartj/ehi754

51. 51.

    Cannon CP, Husted S, Harrington RA, for the DISPERSE-2 Investigators, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844-1851.

    Not in our library10.1016/j.jacc.2007.07.053

52. 52.

    Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852-1856.

    Not in our library10.1016/j.jacc.2007.07.058

53. 53.

    James S, Åkerblom A, Cannon C, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157:599-605.

    Not in our library10.1016/j.ahj.2009.01.003

Cited by papers we hold 1

• Carbohydrate-based drugs launched during 2000−2021 · 2022
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.